SUNDAR JAGANNATH, M.D.; KAREL A. DICKE, M.D., Ph.D.; JAMES O. ARMITAGE, M.D.; FERNANDO F. CABANILLAS, M.D.; LEONARD J. HORWITZ, M.D.; LIJDA VELLEKOOP, M.D.; AXEL R. ZANDER, M.D.; GARY SPITZER, M.D.
JAGANNATH S, DICKE KA, ARMITAGE JO, CABANILLAS FF, HORWITZ LJ, VELLEKOOP L, et al. High-Dose Cyclophosphamide, Carmustine, and Etoposide and Autologous Bone Marrow Transplantation for Relapsed Hodgkin's Disease. Ann Intern Med. 1986;104:163-168. doi: 10.7326/0003-4819-104-2-163
Download citation file:
Published: Ann Intern Med. 1986;104(2):163-168.
Thirty patients with relapsed Hodgkin's disease were treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) and autologous bone marrow transplantation. The median age of the patients was 28 years, and 18 were male. More than half had extranodal sites of relapse and constitutional symptoms. Most had been heavily pretreated with multiple salvage chemotherapy regimens and radiotherapy. At the time of transplantation, 23 patients were having progressive disease despite salvage chemotherapy. High-dose CBV chemotherapy induced complete responses in 15 patients and partial responses in 10 patients. Eleven patients are still in complete remission, 1 of whom has had an unmaintained remission for more than 44 months. Toxicity was moderate; all patients had severe myelosuppression requiring supportive therapy, and 1 patient failed to reconstitute her bone marrow. High-dose CBV chemotherapy and autologous bone marrow rescue proved to be effective as salvage therapy for a select group of heavily pretreated patients with relapsed Hodgkin's disease.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only